David Topper - Sep 21, 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Signature
/s/ Masaru Matsuda, Attorney-in-Fact, for David Topper
Stock symbol
ARQT
Transactions as of
Sep 21, 2024
Transactions value $
-$110,264
Form type
4
Date filed
9/25/2024, 09:42 PM
Previous filing
Apr 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Award $0 +60K +54.55% $0.00 170K Sep 21, 2024 Direct F1
transaction ARQT Common Stock Sale -$110K -11.6K -6.84% $9.48 158K Sep 24, 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs"), initially granted on June 20, 2024, in which the shares were subject to a performance-based vesting condition, which was deemed satisfied on September 21, 2024 (the "Vesting Commencement Date"). Therefore, 50% of the shares vested on September 21, 2024 and the remaining 50% of the shares vest on September 21, 2025, subject to the Reporting Person's continued service with the Company through the applicable vesting date.
F2 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable tax withholding.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.40 to $9.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.